Plain-English translation of NCT07269717 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called HRS-1893 to see if it can help people with a specific type of heart failure called heart failure with preserved ejection fraction (HFpEF). In this condition, the heart doesn't pump blood out efficiently even though the pumping chambers appear to squeeze normally. The researchers want to find out if this medication is safe and tolerable for people living with this condition.
Many people with this type of heart failure struggle with symptoms like shortness of breath and fatigue, but treatment options are limited. This trial is testing whether this new medication could provide a safe way to help relieve these symptoms and improve quality of life.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either take the new medication HRS-1893 or a placebo (inactive pill) daily. You will visit the clinic multiple times for heart tests, blood work, and symptom assessments to help the doctors understand how the medication is working and whether it is safe. The study involves about 48 people total across multiple centers, and your doctors will carefully monitor your heart health throughout your participation.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Enrollment target
~48 participants
Started
March 2026
Primary completion
March 2027
Age range
40 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianhong Lv
Shandong Suncadia Medicine Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.